GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Study Overview
=================
Brief Summary
-----------------
This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively observing whether the stomach is empty as expected, or contains solid or clinically relevant liquid contents.

Official Title
-----------------
GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Conditions
-----------------
Gastric Content Aspiration

Intervention / Treatment
-----------------
* Other: Esophagogastroduodenoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Adults 18 years of age and older presenting for esophagogastroduodenoscopy (EGD) One of the following groups: GLP-1 receptor agonist cohort: active treatment with any GLP-1 receptor agonist therapy within prior 30 days Control cohort: not taking a GLP-1 receptor agonist medication Appropriately fasted per ASA Fasting Guidelines Exclusion Criteria Simultaneous bowel preparation/planned dual endoscopy with colonoscopy Any pre-planned alteration to standard fasting guidelines (ASA NPO guidelines) Emergency endoscopic procedure Concern for active GI bleeding Food impaction/foreign body as indication for procedure Gastric outlet obstruction/bowel obstruction Achalasia Zenker's diverticulum History of esophageal or gastric surgery Active pregnancy Chronic daily opioid therapy ≥ 15 MMEs per day Prokinetic agent use (i.e. metoclopramide) Inability or unwillingness of subject to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients taking a GLP-1 agonist medication<br>Participants meeting all inclusion/exclusion criteria who are taking a GLP-1 agonist medication | Other: Esophagogastroduodenoscopy<br>* All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.<br>|
| Controls<br>Participants meeting all inclusion/exclusion criteria and are NOT taking a GLP-1 agonist medication. | Other: Esophagogastroduodenoscopy<br>* All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retained gastric food | Incidence of clinically significant retained gastric food, defined as visible solid/particulate matter, or liquid volume > 1.5cc/kg | From time of enrollment until the end of surgery, assessed up to 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of pulmonary aspiration event |  | From the time surgery begins until the end of scheduled surgery, assessed up to 24 hours |